Review of late-breaking clinical trials from Cardiovascular Research Technologies (CRT) 2024.

[1]  Biao Li,et al.  CT-guided ozone-mediated lumbar-renal sympathetic denervation for resistant hypertension treatment: A pilot single-arm clinical trial. , 2024, Cardiovascular revascularization medicine : including molecular interventions.

[2]  F. Jaffer,et al.  Paclitaxel-Coated Balloon vs Uncoated Balloon for Coronary In-Stent Restenosis: The AGENT IDE Randomized Clinical Trial. , 2024, JAMA.

[3]  Utku Gülan,et al.  A fully automated artificial intelligence-driven software for planning of transcatheter aortic valve replacement. , 2024, Cardiovascular Revascularization Medicine.

[4]  V. Babaliaros,et al.  Transcatheter Myotomy to Reduce Left Ventricular Outflow Obstruction. , 2024, Journal of the American College of Cardiology.

[5]  Y. Ko,et al.  Stopping Aspirin Within 1 Month After Stenting for Ticagrelor Monotherapy in Acute Coronary Syndrome: The T-PASS Randomized Noninferiority Trial , 2023, Circulation.

[6]  M. Morice,et al.  First randomised controlled trial comparing the sirolimus-eluting bioadaptor with the zotarolimus-eluting drug-eluting stent in patients with de novo coronary artery lesions: 12-month clinical and imaging data from the multi-centre, international, BIODAPTOR-RCT , 2023, EClinicalMedicine.

[7]  P. Teirstein,et al.  4-Year Outcomes of Patients With Aortic Stenosis in the Evolut Low Risk Trial. , 2023, Journal of the American College of Cardiology.

[8]  C. Manisty,et al.  Computed Tomography Cardiac Angiography Before Invasive Coronary Angiography in Patients With Previous Bypass Surgery: The BYPASS-CTCA Trial , 2023, Circulation.

[9]  M. Price,et al.  Optical Coherence Tomography-Guided versus Angiography-Guided PCI. , 2023, The New England journal of medicine.

[10]  B. Lewis,et al.  2023 ESC Guidelines for the management of acute coronary syndromes. , 2023, European heart journal.

[11]  Deepak L. Bhatt,et al.  Defining Strategies of Modulation of Antiplatelet Therapy in Patients With Coronary Artery Disease: A Consensus Document from the Academic Research Consortium , 2023, Circulation.

[12]  E. Boersma,et al.  Immediate versus staged complete revascularisation in patients presenting with acute coronary syndrome and multivessel coronary disease (BIOVASC): a prospective, open-label, non-inferiority, randomised trial , 2023, The Lancet.

[13]  Theresa M. Beckie,et al.  2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. , 2021, Circulation.

[14]  D. Buccheri,et al.  Drug-Coated Balloon Versus Drug-Eluting Stent for Small Coronary Vessel Disease: PICCOLETO II Randomized Clinical Trial. , 2020, JACC. Cardiovascular interventions.

[15]  S. Kapadia,et al.  Self-expanding intra-annular versus commercially available transcatheter heart valves in high and extreme risk patients with severe aortic stenosis (PORTICO IDE): a randomised, controlled, non-inferiority trial , 2020, The Lancet.

[16]  Y. Jang,et al.  Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial. , 2020, JAMA.

[17]  A. M. Leone,et al.  Fractional Flow Reserve or Optical Coherence Tomography to Guide Management of Angiographically Intermediate Coronary Stenosis: A Single-Center Trial. , 2020, JACC. Cardiovascular interventions.

[18]  P. Serruys,et al.  Time-Varying Outcomes With the Absorb Bioresorbable Vascular Scaffold During 5-Year Follow-up: A Systematic Meta-analysis and Individual Patient Data Pooled Study. , 2019, JAMA cardiology.

[19]  Yida Tang,et al.  Drug-Coated Balloon Versus Drug-Eluting Stent for Small-Vessel Disease: The RESTORE SVD China Randomized Trial. , 2018, JACC. Cardiovascular interventions.

[20]  K. Kuck,et al.  Transcatheter Aortic Valve Replacement With a Repositionable Self-Expanding Prosthesis: The PORTICO-I Trial 1-Year Outcomes. , 2018, Journal of the American College of Cardiology.

[21]  S. Winkler,et al.  Drug-coated balloons for small coronary artery disease (BASKET-SMALL 2): an open-label randomised non-inferiority trial , 2018, The Lancet.

[22]  P. Teirstein,et al.  Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease. , 2015, The New England journal of medicine.

[23]  A. Colombo,et al.  A randomized multicenter study comparing a paclitaxel drug-eluting balloon with a paclitaxel-eluting stent in small coronary vessels: the BELLO (Balloon Elution and Late Loss Optimization) study. , 2012, Journal of the American College of Cardiology.